Non-small Cell Lung Cancer Stage I Clinical Trials

13 recruitingLast updated: June 17, 2026

There are 13 actively recruiting non-small cell lung cancer stage i clinical trials across 7 countries. Studies span Phase 2, Phase 1, Early Phase 1, Not Applicable. Top locations include Middletown, New Jersey, United States, Montvale, New Jersey, United States, Commack, New York, United States. Updated daily from ClinicalTrials.gov.


Non-small Cell Lung Cancer Stage I Trials at a Glance

13 actively recruiting trials for non-small cell lung cancer stage i are listed on ClinicalTrialsFinder across 6 cities in 7 countries. The largest study group is Phase 2 with 8 trials, with the heaviest enrollment activity in Middletown, Montvale, and Commack. Lead sponsors running non-small cell lung cancer stage i studies include Memorial Sloan Kettering Cancer Center, Case Comprehensive Cancer Center, and Akeso.

Browse non-small cell lung cancer stage i trials by phase

Treatments under study

About Non-small Cell Lung Cancer Stage I Clinical Trials

Looking for clinical trials for Non-small Cell Lung Cancer Stage I? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Non-small Cell Lung Cancer Stage I trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Non-small Cell Lung Cancer Stage I clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 2

Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer

Non-small Cell Lung CancerMetastatic Squamous Non-Small Cell Lung CarcinomaNon-Small Cell Lung Cancer (Stage III)+5 more
Genelux Corporation142 enrolled15 locationsNCT06463665
Recruiting
Phase 2

Pulmonary Rehabilitation in Advanced Lung Cancer Survivors

Lung CancerNon-small Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+1 more
Case Comprehensive Cancer Center85 enrolled1 locationNCT07104630
Recruiting
Phase 1Phase 2

Alectinib Pharmacokinetic in Patients With NSCLC

ALK Gene MutationNon-small Cell Lung Cancer Stage IIIB
Instituto Nacional de Cancerologia de Mexico45 enrolled1 locationNCT05713006
Recruiting
Phase 2

A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease

Non-small Cell Lung CancerNSCLCNSCLC Stage II+5 more
Memorial Sloan Kettering Cancer Center25 enrolled7 locationsNCT07323732
Recruiting
Phase 2

A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer

Non-small Cell Lung CancerNon-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIIB+1 more
Memorial Sloan Kettering Cancer Center14 enrolled10 locationsNCT07428044
Recruiting
Phase 2

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)Non-small Cell Lung Cancer Stage I+1 more
Stanford University80 enrolled1 locationNCT04585477
Recruiting
Phase 2

Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Stage IV+2 more
University of California, Davis56 enrolled1 locationNCT07250477
Recruiting
Early Phase 1

[177Lu]Lu-AKIR001 First-in-human Study

Thyroid Gland Anaplastic CarcinomaPoorly Differentiated Thyroid CarcinomaCancer Head and Neck+3 more
Karolinska University Hospital15 enrolled1 locationNCT06639191
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients

Non-small Cell Lung Cancer MetastaticSmall Cell Lung CancerNon-Small Cell Lung Cancer (Stage III)+3 more
AIO-Studien-gGmbH12,400 enrolled1 locationNCT02622581
Recruiting

Oral Chemotherapeutic Drugs Were Analyzed in Patients With Driver Gene Negative Locally Advanced/Advanced Non-small Cell Lung Cancer With PS Score 2 A Prospective, Single-arm, Multicenter, Observational Study on the Efficacy and Safety of Radiochemotherapy Combined With PD-1 Inhibitor

Non-small Cell Lung Cancer Stage IIIB/IV
Guangzhou Institute of Respiratory Disease30 enrolled1 locationNCT06310915
Recruiting

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse

Non-small Cell Lung Cancer Stage IIIA
University Hospital, Toulouse60 enrolled1 locationNCT05732974
Recruiting
Not Applicable

Effect and Long-Term Outcomes of Indocyanine Green Fluorescence Imaging Method Versus Modified Inflation-Deflation Method in Identification of Intersegmental Plane(IMPLANE-0529)

SegmentectomyNon-small Cell Lung Cancer Stage I
The First Affiliated Hospital of Nanchang University272 enrolled1 locationNCT05453721